Clinical trials: Carcinoma of Lung
Lung Cancer (NSCLC)
DC/NK Cell Therapy
Primary Outcomes The primary objective of this trial is to test the safety of formulations containing dendritic cells (DCs) and natural killer (NK) cells cultured in vitro.
- Trial name
- NCT07202611
- Testing
- In vitro culture of autologous dendritic and natural killer cells for the treatment of patients with non-small cell lung cancer
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- National Taiwan University Clinical Trial Center
Small-cell Lung Cancer, Small Cell Lung Carcinoma
Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC
In this Single arm study, histologically or cytologically confirmed ED-stage small cell lung cancer (SCLC) patients resistant to or relapsed after standard chemotherapy will be enrolled to investigate the Efficacy and Safety of a…
- Conditions
- Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Recurrent, Small Cell Lung Cancer Extensive Stage
- Trial name
- NCT03994744
- Testing
- PD-1 inhibitor, Metformin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Hunan Cancer Hospital
Lung Cancer
Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiosurgery in treating…
- Trial name
- NCT00852644
- Testing
- computed tomography, fludeoxyglucose F 18, hypofractionated radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Boston Medical Center
Lung Cancer
Pneumonitis After Radiotherapy for Lung Cancer
Major goals of radiotherapy include local disease control and improvement of the patients' prognoses. One possible side effect of radiotherapy for lung cancer is radiation pneumonitis.
- Trial name
- PARALUC (NCT04335409)
- Testing
- Questionnaire, Mobile Application
- Where
- Germany
- Volunteers
- 57 people
- Sponsor
- University Hospital Schleswig-Holstein
Non Small Cell Lung Cancer
PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)
In this feasibility study, a zirconium-89 (89Zr)-avelumab positron emission tomography (PET) scan will be performed in 37 patients prior to treatment with avelumab to: 1.
- Trial name
- PINNACLE (NCT03514719)
- Testing
- 89Zr-avelumab PET, Avelumab
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Radboud University Medical Center
Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
- Trial name
- DeLLphi-312 (NCT07005128)
- Testing
- Tarlatamab, Durvalumab, Carboplatin
- Where
- 164 sites in United States, Argentina and 24 more
- Volunteers
- 350 people
- Sponsor
- Amgen
NSCLC
Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients
This observational study explores associations between drug trough-levels and clinical outcomes in Non Small Cell Lung Cancer (NSCLC) patients treated with immunotherapy (pembrolizumab) either alone or combined with chemotherapy.
- Trial name
- Oncomabs (NCT04557007)
- Testing
- Pembrolizumab
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Oslo University Hospital
Carcinoma, Non Small Cell Lung
Healthy Directions After Lung Surgery Pilot
The objective of this proposal is to test the feasibility and acceptability of a lifestyle risk reduction intervention for patients with lung cancer receiving surgical treatment.
- Trial name
- NCT02135211
- Testing
- Lifestyle counseling
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
Lung Adenocarcinoma
Molecular Analysis of 150 Lung Adenocarcinoma
LUNG-EST is a retrospective study including 152 patients who benefit from lung surgery during the years 2012 to 2013 at Hospices civils de Lyon and with a diagnosis of lung adenocarcinomas.
- Trial name
- LUNG-EST (NCT02843711)
- Testing
- Sequencing
- Where
- France
- Volunteers
- 152 people
- Sponsor
- Hospices Civils de Lyon
Small Cell Lung Cancer
Trial of BMS-986012 in Combination With Platinum and Etoposide
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
- Trial name
- NCT02815592
- Testing
- BMS-986012, Cisplatin, Etoposide
- Where
- 4 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
This research study is studying a drug intervention as a possible treatment for lung cancer. The drugs involved in this study are: Nivolumab Carboplatin Pemetrexed Ipilimumab
- Trial name
- NCT03256136
- Testing
- Carboplatin, Nivolumab, pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Advanced Cancer
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families.
- Trial name
- NCT02219711
- Testing
- MGCD516
- Where
- 43 sites in United States, South Korea
- Volunteers
- 193 people
- Sponsor
- Mirati Therapeutics Inc.
Lung Cancer
Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT01207011
- Testing
- Amrubicin hydrocloride, Docetaxel
- Where
- Japan
- Volunteers
- 202 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Non Small Cell Lung Cancer
Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy
VeriStrat® is a pretreatment blood-based test correlated with clinical outcome after EGFR-TKI therapy in non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT02055144
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Non-small Cell Lung Cancer, Bone Metastasis
Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer
This study will give comparison of the bone pain remission and the adverse reaction of Zoledronic acid combine with High dose fractionation radiotherapy(30Gy/10f) and Zoledronic acid combine with low dose fractionation…
- Trial name
- NCT02480634
- Testing
- Zoledronic acid, Radiotherapy
- Volunteers
- 280 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Lung Cancer Metastatic, Nodes, Lung
Neck Ultrasound by Respiratory Physicians in Patients With Lung Cancer
This is a study of routine neck ultrasound performed by respiratory physicians in patients with mediastinal lymphadenopathy and suspected lung cancer
- Trial name
- NCT03970564
- Testing
- Neck ultrasound guide lymph node sampling
- Where
- Ireland
- Volunteers
- 30 people
- Sponsor
- University College Hospital Galway
Lung Cancer
In-hospital Physiotherapy for Patients Undergoing Thoracic Surgery - a Randomized Controlled Trial
Lung cancer is one of the most common types of cancer in the world, and the cancer that causes the most number of deaths. In Sweden, about 3700 persons are diagnosed every year.
- Trial name
- NCT01961700
- Testing
- Physiotherapy
- Where
- Sweden
- Volunteers
- 107 people
- Sponsor
- Region Örebro County
Lung Cancer
Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy
The goal of this clinical research study is to evaluate the outcome of a standard radiation treatment called stereotactic radiotherapy (SRT) for NSCLC.
- Trial name
- NCT02357992
- Testing
- Stereotactic Body Radiotherapy (SABR)
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2)…
- Trial name
- NCT04380636
- Testing
- Pembrolizumab, Olaparib, Etoposide
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 870 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer, Adult Soft Tissue Sarcoma
Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic…
- Conditions
- Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer
- Trial name
- NCT00020267
- Testing
- interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.